Sofwave Medical Reports Second Quarter and First Half 2023 Financial Results and Recent Business Highlights
Second quarter revenue of $12.4M, +53% year-over-year growth Second quarter pulse recurring revenue of $3.3M, +100% year-over-year growth First half revenue of $22.8M, +67% year-over-year growth, gross margin of 74.2%.
Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Treatment of Acne Scars
FDA clearance supported by a clinical study (n=67) and demonstrated treatment safety and efficacy utilizing SUPERB™, 97% of the treated participants in the trial showed improvement in the appearance of acne scars as assessed by masked evaluations